Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with clonal expansion of small lymphocytes. Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a first-line treatment option, and recent data suggest that strict adherence is directly related to clinical outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Garner, Lauren M., Kline, Theresa, Miller, Jordan, Deal, Allison, Zhu, Anqi, Sketch, Margaret R., Coombs, Catherine C., Muluneh, Benyam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Research & Scholarship
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844188/
https://www.ncbi.nlm.nih.gov/pubmed/33552659
http://dx.doi.org/10.6004/jadpro.2021.12.1.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844188/
https://www.ncbi.nlm.nih.gov/pubmed/33552659
http://dx.doi.org/10.6004/jadpro.2021.12.1.2

Ejemplares similares